Hello Guest, Welcome to Apnea Board !
As a guest, you are limited to certain areas of the board and there are some features you can't use.
To post a message, you must create a free account using a valid email address.

or Create an Account


New Posts   Today's Posts

international Journal of Obeasity Clinical Trial
#1
Abstract
Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: The SCALE Sleep Apnea randomized clinical trial

BACKGROUND: Obesity is strongly associated with prevalence of obstructive sleep apnea (OSA), and weight loss has been shown to reduce disease severity.

OBJECTIVE: To investigate whether liraglutide 3.0 mg reduces OSA severity compared to placebo using the primary endpoint of change in apnea–hypopnea index (AHI) after 32 weeks. Liraglutide’s weight loss efficacy was also examined.

SUBJECTS/METHODS: In this randomized, double-blind trial, non-diabetic participants with obesity who had moderate (AHI 15–29.9 events/h) or severe (AHI greater than or equal to30 events/h) OSA and were unwilling/unable to use continuous positive airway pressure therapy were randomized for 32 weeks to liraglutide 3.0 mg (n=180) or placebo (n=179), both as adjunct to diet (500 kcal/day deficit) and exercise. Baseline characteristics were similar between groups (mean age 48.5 years, males 71.9%, AHI 49.2 events/h, severe OSA 67.1%, body weight 117.6 kg, BMI 39.1 kg/m2, prediabetes 63.2%, HbA1c 5.7%).

RESULTS: After 32 weeks, the mean reduction in AHI was greater with liraglutide than with placebo (−12.2 vs −6.1 events/h, estimated treatment difference [ETD]: −6.1 events/h [95% CI, −11.0 to −1.2], P=0.0150). Liraglutide produced greater mean percentage weight loss compared with placebo (−5.7 vs −1.6%, ETD: −4.2% [95% CI, −5.2 to −3.1%], P<0.0001). A statistically significant association between the degree of weight loss and improvement in OSA endpoints (P<0.01, all) was demonstrated post hoc. Greater reductions in glycated hemoglobin (HbA1c) and systolic blood pressure (SBP) were seen with liraglutide versus placebo (both P<0.001). The safety profile of liraglutide 3.0 mg was similar to that seen with doses less than or equal to1.8 mg.

CONCLUSION: As an adjunct to diet and exercise, liraglutide 3.0 mg was generally well-tolerated and produced significantly greater reductions than placebo in AHI, body weight, SBP and HbA1c in participants with obesity and moderate/severe OSA. The results confirm that weight loss improves OSA-related parameters.

1Toronto Sleep Institute, MedSleep and University of Toronto, Toronto, ON, Canada
2School of Medicine, Temple University, Philadelphia, PA, USA
3Clinilabs and Sleep Disorders Institute, New York, NY, USA
4NeuroTrials Research, Atlanta, GA, USA
5Weill Cornell Medical College, New York, NY, USA
6Perelman School of Medicine, University of Pennsylvania, PA, USA
7Novo Nordisk A/S, Søborg, Denmark
8School of Medicine, Stanford University, Palo Alto, CA, USA

Correspondence: Dr A Blackman, MedSleep, Toronto Sleep Insitute, 586 Eglinton Avenue East, Suite 208, Toronto, Ontario M4P 1P2, Canada. E-mail: adamb@medsleep.com

9A complete list of investigators in the Satiety and Clinical Adiposity—Liraglutide Evidence in non-diabetic and diabetic individuals (SCALE) study group is provided in the Online-Only Supplement

A Blackman1, G D Foster2, G Zammit3, R Rosenberg4, L Aronne5, T Wadden6, B Claudius7, C B Jensen7 and E Mignot8 on behalf of the SCALE study group

Received 7 August 2015; Revised 25 February 2016; Accepted 4 March 2016
Accepted article preview online 23 March 2016



REGISTRATION: clinicaltrials.gov Identifier—NCT01557166
2004-Bon Jovi
it'll take more than a doctor to prescribe a remedy

Observations and recommendations communicated here are the perceptions of the writer and should not be misconstrued as medical advice.
Post Reply Post Reply
#2
I don't like seeing drugs "advertised" on this site. Just my personal opinion.
Inspired
Bigwink
Post Reply Post Reply
#3
(03-29-2016, 02:56 PM)Inspired Wrote: I don't like seeing drugs "advertised" on this site. Just my personal opinion.

I mostly agree, I am sure it was posted with good intentions, but I mostly agree with you.
I am not a Medical professional and I don't play one on the internet.
Started CPAP Therapy April 5, 2016
I'd Rather Be Sleeping
Post Reply Post Reply


#4
These patients were very morbidly obese BMI 39.1 kg/m2, and the intervention group "improved" from severe OSA AHI 49.2 to still severe OSA AHI 37. So any readers should not get a take-home message to ditch the CPAP!

Also given the population was morbidly obese, I wonder whether they excluded obesity hypoventillation syndrome which does get better with weight loss, and, as always the bugbear of weight-loss - how long will the weight stay off?
Post Reply Post Reply


Possibly Related Threads...
Thread Author Replies Views Last Post
  Dreamstation auto-trial mode jacl 30 1,054 03-02-2017, 07:10 PM
Last Post: jacl
Information Newbie APAP Equipment Trial Journal Snoopy.pa30 12 590 02-25-2017, 10:41 AM
Last Post: Snoopy.pa30
  URGENT issue FAA approval for international travel? NCZzzz 13 952 01-01-2017, 12:47 AM
Last Post: robertbuckley
Question Remstar 450P - Does it Have Auto Trial? kacn6771 9 425 12-22-2016, 02:50 PM
Last Post: Sleeprider
  Auto-Trial –delivers CPAP therapy adjusting pressure 30days ICEMAN 8 1,752 09-24-2016, 12:34 PM
Last Post: green wings
  Recent New England Journal of Medicine Abstract elbie 3 390 09-16-2016, 05:34 PM
Last Post: chill
Cool DeVilbiss Intellipap AutoBilevel DV57 Clinical Set Up JessieLC 5 556 07-11-2016, 12:06 AM
Last Post: DeepBreathing

Forum Jump:

New Posts   Today's Posts




About Apnea Board

Apnea Board is an educational web site designed to empower Sleep Apnea patients.

For any more information, please use our contact form.